Jiang et al. (2017) observed that AS-IV inhibits the proliferation and invasion of breast cancer cells in vitro and inhibits tumor growth by down-regulating Vav3 and Rac1/MAPK in vivo (dose 50 mg/kg). In addition, AS-IV at dose of 50–800 μg/mL can reduce the invasion and migration ability of cervical cancer cells (SiHa) by inhibiting pP38 and PI3K, which down-regulates the expression of TGF-β1 (Zhang et al., 2019). This evidence concerns the gene TGFB1 and neoplasm.